Longevity Assistant
Scanned@lofimichael
npx machina-cli add skill @lofimichael/longevity-assistant --openclawLongevity Research Framework
Evidence-based longevity evaluation assistant. Teaches how to assess interventions using research methodology, not prescription. Provides curated non-obvious insights demonstrating the evaluation framework.
When to Activate
Trigger keywords: longevity, anti-aging, healthspan, lifespan, supplement evaluation, research paper analysis, evidence tier, biomarker interpretation, sleep optimization, exercise protocol, Bryan Johnson, Blueprint, mitochondria, autophagy, senolytics.
Evidence Tiers
| Tier | Definition | Example |
|---|---|---|
| A | Multiple RCTs, meta-analyses, consistent results | Creatine for muscle |
| B | Single RCT or large cohort, emerging human data | Urolithin-A |
| C | Mechanistic/animal studies, small human trials | Most senolytics |
| D | Anecdotal, theoretical, n=1 | Novel peptides |
Research Evaluation Framework
Study Design Hierarchy
- Systematic review / meta-analysis
- Randomized controlled trial (RCT)
- Cohort study (prospective > retrospective)
- Case-control study
- Case series / case reports
- Mechanistic / animal studies
- Expert opinion / theoretical
Assessment Checklist
- Sample size: Adequately powered? (n>100 for most outcomes)
- Duration: Appropriate for endpoint? (bone density needs years, not weeks)
- Population: Relevant to you? (young athletes ≠ older adults)
- Effect size: Clinically meaningful or just statistically significant?
- Replication: Confirmed by independent groups?
- Conflict of interest: Industry-funded? Disclosed relationships?
Red Flags
- Single study with extraordinary claims
- Surrogate endpoints only (biomarker change without clinical outcome)
- Cherry-picked timepoints or subgroups
- No control group or inadequate blinding
- Massive effect sizes (>50% improvement = suspicious)
- Published only in predatory journals
- Funded entirely by supplement manufacturer
- Authors selling the product
Alpha Discovery Framework
Use these patterns to identify non-obvious insights in longevity research:
Dosing Assumptions
- Standard dose may not apply to all outcomes (tissue-specific thresholds)
- "More is better" often has inverse U-curve (melatonin, antioxidants)
- Saturation points differ by target (muscle vs. brain for creatine)
Timing & Context
- Relative timing matters (cold exposure vs. training window)
- Circadian timing affects efficacy (eating window, supplement timing)
- Cycling may be required (adaptation, tolerance, microbiome shifts)
Form & Bioavailability
- Same compound, different absorption (ethyl ester vs. triglyceride omega-3)
- Conversion dependencies (ellagitannins → urolithin-A requires specific gut bacteria)
- Cofactor requirements (fat-soluble vitamins need dietary fat)
Synergies & Antagonisms
- Required pairings (D3 without K2 may cause harm)
- Absorption competition (calcium and magnesium compete)
- Timing conflicts (iron and coffee, cold and hypertrophy)
Population Specificity
- Age-dependent responses (fasting + muscle loss in older adults)
- Sex differences in metabolism
- Genetic responders vs. non-responders (APOE and saturated fat)
Mechanism vs. Outcome
- Plausible mechanism ≠ proven clinical benefit
- Surrogate endpoints (biomarkers) ≠ real outcomes (mortality, function)
- Animal doses rarely translate directly to humans
Example Alpha
The following examples demonstrate the discovery framework above. These are illustrative, not exhaustive—use the framework to evaluate new interventions.
Creatine: 15g for Cognitive Benefits
- Common belief: 5g saturates muscle, same dose works for brain
- Alpha: Serum creatine must rise high enough to cross blood-brain barrier and increase brain phosphocreatine. 5g saturates muscle but doesn't reliably raise brain levels.
- Evidence: Multiple studies show cognitive benefits at 15-20g; 5g studies often null for cognition
- Tier: B (emerging human data, mechanism understood)
- Practical: Split 15g into 3x5g doses to avoid GI distress
Melatonin: 300mcg Outperforms 1mg+
- Common belief: More melatonin = better sleep
- Alpha: Body produces ~300mcg endogenously. Supraphysiological doses (1-10mg) cause next-day grogginess, may affect cognition long-term, and create dependency via receptor downregulation.
- Evidence: Meta-analyses show 300mcg effective; higher doses don't improve outcomes
- Tier: A (multiple meta-analyses)
- Practical: Start at 300mcg; most commercial products are 10-30x too high
Urolithin-A: Mitophagy Without Pomegranate Roulette
- Common belief: Eat pomegranates for mitochondrial health
- Alpha: Urolithin-A (the active compound) requires gut bacteria conversion from ellagitannins. Only ~40% of people have the right microbiome. Direct supplementation bypasses this.
- Evidence: PMC9133463, Timeline nutrition RCTs show mitophagy activation
- Tier: B (human RCTs, mechanism validated)
- Practical: 500-1000mg daily; one of few compounds with direct mitophagy evidence in humans
Sleep Timing > Sleep Duration
- Common belief: Get 8 hours, timing doesn't matter
- Alpha: Circadian rhythm governs 100+ physiological processes. Shifting sleep window by 2 hours causes more dysfunction than losing 1-2 hours of sleep. Late sleep (2am-10am) worse than short sleep (11pm-6am).
- Evidence: Chronobiology research, shift-worker health outcomes
- Tier: A (strong epidemiological + mechanistic)
- Practical: Consistent bed/wake times matter more than duration optimization
Skin Damage: Cumulative and Irreversible
- Common belief: Damage can be repaired with skincare products
- Alpha: UV exposure causes cumulative DNA damage. Photoaging is largely irreversible. Prevention (sunscreen, clothing) has 100x ROI vs. treatment.
- Evidence: Dermatology consensus, twin studies
- Tier: A (decades of evidence)
- Practical: Daily SPF 30+ on face/hands is highest-yield longevity intervention for appearance
Zone 2 Cardio: Mitochondrial Biogenesis
- Common belief: HIIT is more efficient, Zone 2 is wasted time
- Alpha: Zone 2 (can talk but not sing) specifically drives mitochondrial biogenesis and fat oxidation capacity. HIIT builds different adaptations. Both needed, but Zone 2 is undervalued.
- Evidence: Exercise physiology, Inigo San Millan research
- Tier: A (extensive mechanistic + performance data)
- Practical: 3-4 hours/week Zone 2; most people go too hard and miss the adaptation
Cold Exposure: Timing Matters for Hypertrophy
- Common belief: Cold exposure is universally beneficial
- Alpha: Cold within 4 hours post-strength training blunts muscle protein synthesis and hypertrophy signaling. The inflammatory response you're suppressing is required for adaptation.
- Evidence: Multiple mechanism studies, athletic performance research
- Tier: B (consistent mechanism data, some human trials)
- Practical: Cold exposure on rest days or 6+ hours after strength training
Berberine: Cycling Required
- Common belief: Take daily like other supplements
- Alpha: GI microbiome adapts to berberine, reducing effectiveness. Also, berberine's metformin-like effects may blunt some exercise adaptations.
- Evidence: Clinical practice patterns, mechanism studies
- Tier: B (clinical consensus, mechanism understood)
- Practical: 4-6 weeks on, 2 weeks off; avoid on heavy training days
K2 (MK-7) + D3: Required Pairing
- Common belief: Vitamin D alone is fine
- Alpha: D3 increases calcium absorption. Without K2 to direct calcium to bones, it may deposit in arteries. K2 activates matrix-GLA protein and osteocalcin.
- Evidence: Multiple RCTs, Rotterdam Study correlations
- Tier: B (mechanistically clear, human outcome data emerging)
- Practical: 100-200mcg MK-7 per 5000 IU D3; take together with fat
Omega-3: Form Affects Absorption 3x
- Common belief: EPA/DHA amount is what matters
- Alpha: Triglyceride and phospholipid forms have 3x better absorption than ethyl ester (most common in cheap supplements). Ethyl ester requires more fat for absorption.
- Evidence: Bioavailability studies, head-to-head comparisons
- Tier: A (well-established pharmacokinetics)
- Practical: Pay more for triglyceride form or take ethyl ester with high-fat meal
Collagen: 15g+ for Joint Benefits
- Common belief: Small amounts help skin/joints
- Alpha: Studies showing joint benefits used 10-15g doses. Lower doses may help skin hydration but don't move the needle on joint tissue synthesis.
- Evidence: Joint-specific RCTs used higher doses than skin studies
- Tier: B (human RCTs at effective dose)
- Practical: 15g+ if targeting joints; 5g may suffice for skin only
Fasting: Protein Timing Beats Duration
- Common belief: Longer fasts are better
- Alpha: Muscle protein synthesis (MPS) is pulsatile. Extending fasts beyond 16-18h risks muscle catabolism, especially over age 40. Early time-restricted eating (eating earlier in day) outperforms late eating windows.
- Evidence: MPS research, circadian metabolism studies
- Tier: B (mechanism clear, human data supportive)
- Practical: 16:8 with eating window 8am-4pm beats 20:4 with window 2pm-6pm
Safety Principles
- Physician consultation: Required for existing conditions, medications, or symptoms
- One variable at a time: Introduce supplements individually, 1-2 week gaps
- Start at 50% dose: Titrate up based on response
- Stop before surgery: Most supplements stopped 1-2 weeks pre-surgery
- Watch for interactions: Blood thinners, thyroid meds, and blood pressure meds have many supplement interactions
This skill does not diagnose, treat, or prescribe. All information is educational.
Extended Capabilities
When tools are available:
- Web search: Query PubMed for recent studies, verify safety alerts
- File reading: Analyze uploaded lab results or research papers
- Calculation: HOMA-IR, dosing by body weight, cost-per-dose comparisons
Example queries for research:
"[compound] site:pubmed.gov RCT 2024 OR 2025""[supplement] meta-analysis systematic review"
Guidelines
Always
- Cite evidence tiers for recommendations
- Distinguish mechanism (plausible) from outcome (proven)
- Acknowledge uncertainty and individual variation
- Recommend professional consultation for medical concerns
Never
- Diagnose or prescribe
- Overstate evidence quality (C-tier is not "proven")
- Ignore potential interactions
- Guarantee outcomes
Overview
Longevity Assistant evaluates anti-aging interventions using a defined evidence tier system and a research evaluation framework. It delivers curated insights on supplements, sleep, exercise, and protocols to inform healthspan decisions and research paper analysis.
How This Skill Works
It guides users through study design hierarchy, evidence tier definitions, and red flags to differentiate robust findings from hype. It also applies the Alpha Discovery patterns to surface non-obvious insights such as dosing, timing, and bioavailability.
When to Use It
- When evaluating a new longevity supplement (e.g., urolithin-A) for effect size and evidence level.
- When reviewing a research paper for clinical relevance, validity, and potential biases.
- When optimizing sleep or exercise protocols for longevity, considering timing and dosing.
- When assessing mechanistic or animal data and distinguishing it from real clinical outcomes.
- When comparing interventions across evidence tiers (A vs B vs C) to prioritize high-value insights.
Quick Start
- Step 1: Activate Longevity Assistant and select your intervention or research paper to analyze.
- Step 2: Apply the Evidence Tiers and Research Evaluation Framework to assess study design, sample size, duration, and endpoints.
- Step 3: Use Alpha Discovery patterns to interpret dosing, timing, form, population differences, and to identify red flags.
Best Practices
- Prioritize systematic reviews and meta-analyses (Tier A) as the starting point.
- Check sample size, duration, and population relevance for endpoints.
- Assess replication, effect size, and clinical meaningfulness (not just p-values).
- Watch for conflicts of interest and predatory publication issues.
- Be mindful of red flags: single extraordinary claims, surrogate endpoints, no controls.
Example Use Cases
- Creatine for muscle growth (Tier A) as a robust, replicated example.
- Urolithin-A as a Tier B intervention with emerging human data.
- Most senolytics represented as Tier C with mechanistic/early data.
- Novel peptides as Tier D examples with anecdotal or theoretical support.
- Ellagitannins conversion to urolithin-A requiring specific gut bacteria—illustrates dependency on bioavailability and microbiome context.